Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
30-minute panitumumab infusion with FOLFOX in RAS wild-type unresectable advanced or recurrent colorectal cancer
jRCTs041260128Recruiting
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of panitumumab in colorectal cancer (CRC). Primary endpoint: Incidence of Grade 3 or higher infusion reactions during short-duration panitumumab infusion. Started Sep 2026; status: recruiting.
02
Drugs
panitumumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCTs041260128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041260128.